Study Document
Sponsored by Roche Laboratories, a Thesis
Pages:3 (890 words)
Sources:2
Subject:Health
Topic:Breast Cancer
Document Type:Thesis
Document:#61716681
The sample population for the stomach cancer trials included 594 patients that were Her2 positive. It is not known if patients in the stomach cancer trial included both males and females. Exclusionary criteria were not made available for either of the studies. All of the patients were receiving standard chemotherapy treatments, in addition to receiving Herceptin (Pollack, 2009). The sample populations for these studies were large for a clinical trial. Many times, it is difficult to find patients that fit the criteria for inclusion in the study. This was not a problem for these studies. The sample population of the study improves the validity of the study and confidence in the drug to be effective in patients that meet the criteria for administration of Herceptin.
The study design in both cases used a comparative study. One group was the test group and would receive the treatment being tested, in this case Herceptin. The other group would be the control group and would not receive the drug. Although it was not revealed in the article, many clinical trials at this stage are double-blind studies. In this study technique, a sham treatment is designed that mimics the real treatment, only without the active ingredients. Neither the doctor, nor the patient knows which study group to which they belong. They do not know if they have received the real or sham treatment. This helps to eliminate external bias in the study and improvise the validity of the results obtained.
Conclusion
The results of the stomach cancer study found that patients that received Herceptin, in addition to standard chemotherapy, lived an average of 13.8 months, as compared to 11.1 months for those that received chemotherapy alone (Pollack, 2009). In the triple negative breast cancer study, those that received Herceptin in addition to standard chemotherapy lived an average of 9.2 months, as compared to 5.7 months for those that received chemotherapy alone.
This article outlined two major studies, one for triple negative breast cancer and one for stomach cancer. It also mentioned several other minor studies. The focus of the article was on the use of Herceptin in difficult to treat cancers. Both the stomach cancer trial and the triple negative breast cancer trial demonstrated the ability of Herceptin to slow the progress of cancer and significantly extended the lives of cancer patients. With the information provided, one must agree with the conclusion that Herceptin is effective in extending the lives of patients with advanced, difficult to treat types of cancer.
References
F. Hoffman-L Roche Ltd. (2009). Herceptin (Trastuuzumab). Retrieved June 6, 2009 from http://www.roche.com/products/product-details.htm?type=product&id=102.
Pollack, A. (2009). Promising Results in Stomach and Breast Cancer Drugs. The New…
Sample Source(s) Used
References
F. Hoffman-L Roche Ltd. (2009). Herceptin (Trastuuzumab). Retrieved June 6, 2009 from http://www.roche.com/products/product-details.htm?type=product&id=102.
Pollack, A. (2009). Promising Results in Stomach and Breast Cancer Drugs. The New York
Times. May 31. 2009. Retrieved June 7, 2009 from http://www.nytimes.com/2009/06/01/business/01drug.html
Related Documents
Study Document
Direct to Consumer Advertising History of Drug
Direct to Consumer Advertising HISTORY OF DRUG ADVERTISING THE DTC ADVERTISING PHENOMENON CREATING DEMAND DECEPTIVE ADVERTISING - A WOLF IN SHEEP'S CLOTHING CAUSE OF DEATH PROFIT UTILIZATION, PRICING, AND DEMOGRAPHICS LEGISLATION, POLITICS AND PATENTS LEGISLATIVE INITIATIVES REGARDING DTC RECALLED and/or DEADLY DRUGS In order to provide the most efficient method of evaluation, the study will utilize existing stores of qualitative and quantitative data from reliable sources, such as U.S. Government statistical references, University studies, and the studies and publications of non-profit
Study Document
Pharmaceutical Industry the Purpose of
This relationship has an effect on the payment rates that CMS sets. Higher cost pharmaceutical therapies are systematically reimbursed below acquisition cost (i.e., the payment system is biased against full reimbursement for higher cost therapies). Reimbursement compared to acquisition cost for the top IO pharmaceuticals by total expenditures indicates that 9 of the 10 are significantly under reimbursed." Clinical Trials Report: Congress established Medicare beneficiaries numbering 40 million with a prescription
Study Document
Global Leaders As the 21st Century Unfolds,
Global Leaders As the 21st century unfolds, we are told that the world is embracing globalism -- a key change in the economic, political and cultural movements that, broadly speaking, move the various countries of the world closer together. This idea refers to a number of theories that see the complexities of modern life such that events and actions are tied together, regardless of the geographic location of a specific country
Study Document
Fundamental Analysis of Johnson and Johnson, Inc.
JOHNSON & JOHNSON The Fundamental Analysis of Johnson & Johnson Inc. (J& J, 2005) Economic and Market Analysis Globalization Industry Analysis Company Analysis Brief History of the Company Analysis of Capital Asset Pricing Model Intrinsic Value Valuation Measures Trading Information Competitors Awards & Recognition Our modern business world consists of an extremely competitive global economy where manufactures search for opportunities to strategically reduce costs and increase market share and profitability. Historically, the most often chosen solution for holding down costs was to systematically reduce
Study Document
Japanese-American Biopharmaceutical Industry in the 21st Century
Japanese-American Biopharmaceutical Industry in the 21st Century Optimizing Ethical Drug Availability Between These Two Pharmaceutical Superpowers" The Japanese-American biopharmaceutical industry represents an ongoing international effort between the two top pharmaceutical markets in the world. These two economic powers provide consumers with a majority share of all pharmaceuticals produced in the world. However, a number of pharmaceutical products that are currently available to U.S. residents are unavailable to Japanese consumers. From a humanitarian perspective, this
Study Document
Business Education Training
Mentoring Process in a Business Setting In most professions, the first years in a new position are fraught with uncertainties and problems. The need for supporting teachers and people in other professions was cited as far back as the Conant Report (1963). During the next twenty years, many attempts were make to put effective mentoring programming in place throughout the business world. This study will address the level of mentoring